Loading the peptide page…
Loading the peptide page…
A triple monoamine reuptake inhibitor under study for obesity.
Last reviewed Oct 27, 2026 · How we rate evidence · Report an error
Tesofensine is a compound that blocks the reuptake of noradrenaline, dopamine and serotonin, which can reduce appetite and increase energy expenditure. It was tested for weight loss in a phase 2 obesity trial and, combined with the beta blocker metoprolol (as Tesomet), in people with hypothalamic obesity and Prader-Willi syndrome. The drug is not approved in the United States and is listed as a prohibited stimulant in sport.
Blocks reuptake of noradrenaline, dopamine and serotonin, leading to increased signaling that suppresses appetite and boosts metabolism.
Evidence
3/5
Phase‑2 randomized controlled trials in hypothalamic obesity and Prader‑Willi syndrome; animal studies show metabolic effects.
Half-life
Unknown
Known as
–
Compare Tesofensine with: SemaglutideTirzepatideor any other →
Some human dataSmall or older human trials, or bigger trials with mixed or negative results.
Phase‑2 randomized controlled trials in hypothalamic obesity and Prader‑Willi syndrome; animal studies show metabolic effects. How we rate evidence
In a phase‑2 randomized controlled trial, Tesomet (tesofensine combined with metoprolol) produced significant weight loss in participants with hypothalamic obesity.
In rats, transdermal tesofensine reduced body‑weight gain and improved metabolic markers compared with controls.
“Anecdotal” means reported by users, not shown in controlled trials. Sources
No dose for Tesofensine has been published yet. It’s still in development, so there’s no dose table, calculator or mixing guide here. We’ll add them when trial results or prescribing information report a dose used in people.
An email when its FDA or WADA status changes, or when new research comes out.
Tesofensine is not FDA-approved for any use, and no US marketing application has been filed. In 2021 the FDA granted orphan-drug designation to Tesomet, a fixed combination of tesofensine and the beta blocker metoprolol, for Prader-Willi syndrome and for hypothalamic obesity; a designation supports development and is not an approval. In December 2025 the FDA sent a warning letter to Darmerica, LLC that listed tesofensine among bulk ingredients not eligible for use in compounding.
Regulations change often — verify with the FDA, EMA, MHRA, Health Canada, TGA and WADA before acting.
Evidence rating (3/5): Phase‑2 randomized controlled trials in hypothalamic obesity and Prader‑Willi syndrome; animal studies show metabolic effects.
Legal status: Tesofensine is not FDA-approved for any use, and no US marketing application has been filed. In 2021 the FDA granted orphan-drug designation to Tesomet, a fixed combination of tesofensine and the beta blocker metoprolol, for Prader-Willi syndrome and for hypothalamic obesity; a designation supports development and is not an approval. In December 2025 the FDA sent a warning letter to Darmerica, LLC that listed tesofensine among bulk ingredients not eligible for use in compounding.
See something wrong or out of date? Report an error and we’ll check it against the sources. How we review pages